Literature DB >> 24819172

Association between Toll-like receptor 3 polymorphisms and cancer risk: a meta-analysis.

Daye Cheng1, Yiwen Hao, Wenling Zhou, Yiran Ma.   

Abstract

Toll-like receptors (TLRs) are well known as molecular sensors of pathogen-associated molecular patterns. They control activation of the innate immune response and subsequently shape the adaptive immune response. Polymorphisms in TLR3 gene associated with cancer have been studied extensively. However, the results remain controversial. A literature search was performed among PubMed, Embase, Web of Science, Science Direct, Wanfang, and Chinese National Knowledge Infrastructure databases to identify eligible studies on the association between TLR3 polymorphisms and cancer risk. A total of 12 studies in 11 articles were included in the meta-analysis including 5,861 cases and 6,339 controls. Significant associations with cancer risk were observed for single nucleotide polymorphisms (SNPs) rs3775291 (allele model: odds ratio (OR) = 1.12, 95 % confidence interval (95 % CI) = 1.00-1.25, P = 0.04), rs3775290 (allele model: OR = 1.12, 95 % CI = 1.00-1.25, P = 0.04; dominant model: OR = 1.30, 95 % CI = 1.05-1.60, P = 0.01; homozygous comparison: OR = 1.68, 95 % CI = 1.06-2.68, P = 0.03; heterozygous comparison: OR = 1.25, 95 % CI = 1.01-1.55, P = 0.04), rs5743305 (allele model: OR = 1.07, 95 % CI = 1.01-1.15, P = 0.03; dominant model: OR = 1.11, 95 % CI = 1.01-1.22, P = 0.03), and rs5743312 (allele model: OR = 1.13, 95 % CI = 1.01-1.27, P = 0.03; recessive model: OR = 1.86, 95 % CI = 1.31-2.63, P < 0.01; homozygous comparison: OR = 1.88, 95 % CI = 1.33-2.67, P < 0.01), respectively. Meanwhile, we did not find any significant association with cancer risk for rs7657186 and rs7668666. In conclusion, this meta-analysis indicates a significant association of four TLR3 gene polymorphisms with cancer risk. However, because the study size was limited, further studies are essential to confirm our results.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24819172     DOI: 10.1007/s13277-014-2049-z

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  51 in total

1.  A Toll-like receptor recognizes bacterial DNA.

Authors:  H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

2.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

Review 3.  IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors.

Authors:  Kenya Honda; Tadatsugu Taniguchi
Journal:  Nat Rev Immunol       Date:  2006-09       Impact factor: 53.106

4.  Operating characteristics of a rank correlation test for publication bias.

Authors:  C B Begg; M Mazumdar
Journal:  Biometrics       Date:  1994-12       Impact factor: 2.571

5.  Single-nucleotide polymorphisms in genes encoding toll-like receptor -2, -3, -4, and -9 in a case-control study with bladder cancer susceptibility in a North Indian population.

Authors:  Vibha Singh; Neena Srivastava; Rakesh Kapoor; Rama Devi Mittal
Journal:  Arch Med Res       Date:  2012-11-06       Impact factor: 2.235

6.  Association of TLR2, TLR3, TLR4 and CD14 genes polymorphisms with oral cancer risk and survival.

Authors:  K Zeljic; G Supic; N Jovic; R Kozomara; M Brankovic-Magic; M Obrenovic; Z Magic
Journal:  Oral Dis       Date:  2013-06-24       Impact factor: 3.511

7.  Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus.

Authors:  Loïc Guillot; Ronan Le Goffic; Sarah Bloch; Nicolas Escriou; Shizuo Akira; Michel Chignard; Mustapha Si-Tahar
Journal:  J Biol Chem       Date:  2004-12-03       Impact factor: 5.157

Review 8.  Toll-like receptor 4 activation in cancer progression and therapy.

Authors:  Alja Oblak; Roman Jerala
Journal:  Clin Dev Immunol       Date:  2011-11-03

9.  Genetic variation in TLR or NFkappaB pathways and the risk of breast cancer: a case-control study.

Authors:  Alexa J Resler; Kathleen E Malone; Lisa G Johnson; Mari Malkki; Effie W Petersdorf; Barbara McKnight; Margaret M Madeleine
Journal:  BMC Cancer       Date:  2013-05-01       Impact factor: 4.430

10.  Poly I:C enhances cycloheximide-induced apoptosis of tumor cells through TLR3 pathway.

Authors:  Qun Jiang; Haiming Wei; Zhigang Tian
Journal:  BMC Cancer       Date:  2008-01-17       Impact factor: 4.430

View more
  3 in total

1.  Chloroquine attenuates LPS-mediated macrophage activation through miR-669n-regulated SENP6 protein translation.

Authors:  Yupeng Long; Xin Liu; Ning Wang; Hong Zhou; Jiang Zheng
Journal:  Am J Transl Res       Date:  2015-11-15       Impact factor: 4.060

2.  Enhancing the immune stimulatory effects of cetuximab therapy through TLR3 signalling in Epstein-Barr virus (EBV) positive nasopharyngeal carcinoma.

Authors:  Louise Soo Yee Tan; Benjamin Wong; Nagaraja Rao Gangodu; Andrea Zhe Ern Lee; Anthony Kian Fong Liou; Kwok Seng Loh; Hao Li; Ming Yann Lim; Andres M Salazar; Chwee Ming Lim
Journal:  Oncoimmunology       Date:  2018-08-27       Impact factor: 8.110

3.  Toll-like receptor 3 L412F polymorphism promotes a persistent clinical phenotype in pulmonary sarcoidosis.

Authors:  G Cooke; I Kamal; M Strengert; E Hams; L Mawhinney; A Tynan; C O'Reilly; D N O'Dwyer; S L Kunkel; U G Knaus; D C Shields; D R Moller; A G Bowie; P G Fallon; C M Hogaboam; M E Armstrong; S C Donnelly
Journal:  QJM       Date:  2018-04-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.